Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/214368
Title: Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study
Author: Mayén, Ana Lucía
Sabra, Mirna
Aglago, Elom K.
Perlemuter, Gabriel
Voican, Cosmin
Ramos, Inés
Debras, Charlotte
Blanco, Jessica
Viallon, Vivian
Ferrari, Pietro
Olsen, Anja
Tjønneland, Anne
Langmann, Fie
Dahm, Christina C.
Rothwell, Joseph
Laouali, Nasser
Marques, Chloé
Schulze, Matthias B.
Katzke, Verena
Kaaks, Rudolf
Palli, Domenico
Macciotta, Alessandra
Panico, Salvatore
Tumino, Rosario
Agnoli, Claudia
Farràs, Marta
Molina Montes, Esther
Amiano, Pilar
Chirlaque, María Dolores
Castilla, Jesús
Werner, Mårten
Bodén, Stina
Heath, Alicia K.
Tsilidis, Kostas
Aune, Dagfinn
Weiderpass, Elisabete
Freisling, Heinz
Gunter, Marc J.
Jenab, Mazda
Keywords: Malalties del fetge
Síndrome metabòlica
Liver diseases
Metabolic syndrome
Issue Date: 3-Jun-2024
Publisher: Springer Science and Business Media LLC
Abstract: Background Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality. Methods We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed. Results Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI >= 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality. Conclusions Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s12916-024-03366-3
It is part of: BMC Medicine, 2024, vol. 22, num. 1
URI: http://hdl.handle.net/2445/214368
Related resource: https://doi.org/10.1186/s12916-024-03366-3
ISSN: 1741-7015
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s12916-024-03366-3.pdf814.5 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons